Orphan drugs in different countries and development of new drugs to treat biliary tract cancer
| Autor: | Fei Ma, Shouhua Wang, Haihong Cheng, Jun Ding, Di Zhou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cisplatin medicine.medical_specialty Chemotherapy Durvalumab Letter business.industry medicine.medical_treatment General Medicine Immunotherapy 030105 genetics & heredity Malignancy medicine.disease Gemcitabine Targeted therapy Orphan drug 03 medical and health sciences 0302 clinical medicine medicine Intensive care medicine business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Intractable Rare Dis Res |
| Popis: | Biliary tract cancer (BTC), which includes cholangiocarcinoma and gallbladder carcinoma, is a rare malignancy. Due to its low incidence, drugs treating these diseases are scarce, so they can be considered orphan drugs. The main treatment choice for BTC is chemotherapy with gemcitabine or cisplatin or combined use of both, but patients fail to significantly benefit from established chemotherapy. Advancements in immunotherapy and targeted therapy will shed light on ways to improve clinical outcomes for patients with BTC. In conjunction, more new drugs will come onto the market. This article compares the conditions for development of orphan drugs in different countries and it describes several types of new drugs that were recently approved to treat BTC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|